A Phase 4 interventional study of Varenicline and placebo in Smoking Cessation, sponsored by Shaare Zedek Medical Center. Completed at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-05.
Sponsored by Shaare Zedek Medical Center · Phase 4, Interventional, and Treatment
SUMMARY Rationale: Worldwide, cigarette smoking carries a high mortality. Since the available cessation programs are not effective for all smokers, new strategies are necessary for tobacco control.
Primary objective: To investigate whether a 6-week varenicline preloading facilitates smoking reduction and cessation compared with the standard varenicline treatment schedule.
Design: Parallel group, double-blind, randomised controlled clinical trial. Participants: Smokers of both sexes from the general population. Methods: Participants will be randomized into two groups of treatment. Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment. Visits will be arranged at randomization, week 4, week 6 (Quit day (QD)) and at week 1, 6, 12, and 24 after QD.
Measurements: These will include vital signs, smoking history, spirometry, expired CO, salivary cotinine, nicotine dependence, and withdrawal symptoms. Primary outcome is continuous abstinence at 6 months.
Sample size: For an estimated difference of quit rates of 15% at 24 weeks (30% for group A vs. 15% for group B) 121 subjects per group are needed (Total = 242 subjects).
Statistical analysis: T tests (rational variables) and x2 test or Fisher's exact test (nominal variables) will be used as appropriate.
Expected benefits: This study might contribute to optimize the current use of varenicline.
Study design:
The study is a parallel group, double-blind, randomised controlled clinical trial. Allocation to treatment will be made when the subject has been entered into the study that is when he/she has fulfilled the inclusion/exclusion criteria (see below). Visits will be arranged at inclusion, at week 4 and 6 (Quit day (QD)) after inclusion, and at week 1, 6, 12, and 24 after QD.
Study population:
Participants will be eligible smokers from throughout Jerusalem, who want to reduce then stop smoking.
Randomisation procedure:
Subjects will be computer-randomised either to an extended varenicline preload treatment or to a regular varenicline schedule. Both groups will receive an identical treatment thereafter.
Blinding:
Due to the nature of the intervention, blinding is possible only during the varenicline preload phase. During this phase, both the study team members and the participants will be blinded to treatment allocation. After week 6 all participants will be receiving the same, active treatment.
Study intervention:
After enrolment the subjects will be randomized to receive either varenicline preloading for 6 weeks (1 mg/day at week 1; 2 mg/day from week 2-6) (Group A) or placebo for 5 weeks and varenicline for 1 week (Group B). Then, subjects in both groups will receive regular treatment with varenicline for 12 weeks according to a schedule depicted on Table 2. Only minimal levels of advice and support will be given. However, all subjects will receive individualized verbal instructions regarding the general conduct of the study and the proper use of the study medication. All participants will be asked to reduce smoking by 50 percent during 6 weeks after inclusion then stop smoking altogether.
At baseline the following data will be collected:
Shaare Zedek Medical Center is the lead sponsor of 191 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Drug: Varenicline
group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Drug: Varenicline · Drug: placebo
Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Also known as: champix, chantix
Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Continuous abstinence
defined as avoidance of tobacco (not a single puff) since the quit date. It will be assessed by self-reported complete abstinence and expired CO \< 10 ppm from week 7 until endpoint. The occurrence of occasional lapses after week 7 will be categorised as a failure in the main evaluation, but will not necessitate withdrawal if the subject is willing to continue and is considered by the investigators as competent to succeed.
Time frame: from week 7 until week 24
smoking reduction
This will be measured by daily self-reported cigarettes per day and expired CO measures (at every visit). An efficient reduction will be defined by a diminution of at least 50% of the number of cigarettes smoked, together with a reduction in CO levels compared to baseline
Time frame: from week 7 until week 24
Decline in pulmonary function
The rate of decline of spirometric parameters will be calculated separately for quitters, continuing smokers and reducers from the two groups, pooled together.
Time frame: from week 7 until week 24
adverse events
The subjects will be asked about adverse events at each visit during treatment by an open-ended question. Serious adverse events are defined as events that are fatal or life threatening, permanently disabling, requiring or prolonging hospitalisation, cancer, congenital abnormality or overdose
Time frame: from week 7 until week 24
Symptoms and physical signs associated with withdrawal: MPSS questionnaire
MPSS questionnaire
Time frame: from week 7 until week 24
Use of cigarettes
For participants smoking at any time point the number of cigarettes smoked per day and the satisfaction (mCEQ questionnaire) will be assessed.
Time frame: from week 7 until week 24
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shaare Zedek Medical Center